中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.038 seconds)

    STENT POSITIONING SYSTEM
    1.
    发明申请
    STENT POSITIONING SYSTEM 审中-公开
    支架定位系统

    公开(公告)号：WO2004103216A1

    公开(公告)日：2004-12-02

    申请号：PCT/IL2004/000436

    申请日：2004-05-23

    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD. ,  VARSHITZKY, Boris ,  BORIVKER, Nachum ,  LOTAN, Chaim ,  MOSSERI, Moriss

    Inventor： VARSHITZKY, Boris ,  BORIVKER, Nachum ,  LOTAN, Chaim ,  MOSSERI, Moriss

    IPC: A61F2/06

    CPC classification number: A61F2/958 ,  A61F2002/821

    Abstract: There is provided a stent positioning system, including an inflatable balloon (22) for expanding a stent, the balloon, in its collapsed state, fitting into and being adapted to carry the stent in its pre-expanded condition; stent locator means slidably accommodated in a guide catheter and adapted to change its shape prior to making contact with the interior wall surface of a major blood vessel in the ostial region of a smaller blood vessel branching off from the major vessel and prior to the expansion of the stent, and mechanical means for changing the shape of the stent locator means; wherein the change of shape enables the locator means (14) to abut the interior wall surface, thereby ensuring correct apposition between the stent and the ostium of the smaller blood vessel.

    Abstract translation: 提供了一种支架定位系统，该系统包括用于扩张支架的可膨胀气囊（22），气囊处于其折叠状态，装入并适于将支架展开在其预扩张 条件; 支架定位器装置，其可滑动地容纳在导引导管中并且适于在与主血管分叉的较小血管的开口区域中的大血管的内壁表面接触之前且在血管扩张之前改变其形状 支架和用于改变支架定位装置的形状的机械装置; 其中形状的改变使得定位器装置（14）能够邻接内壁表面，由此确保支架与较小血管的口之间的正确对合。

    COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS
    3.
    发明申请
    COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS 审中-公开
    用于治疗或预防骨骼肌肉纤维化的组合物和方法

    公开(公告)号：WO2008087650A2

    公开(公告)日：2008-07-24

    申请号：PCT/IL2008/000088

    申请日：2008-01-21

    Applicant: AGRICULTURAL RESEARCH ORGANIZATION ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD. ,  PINES, Mark ,  NAGLER, Arnon

    Inventor： PINES, Mark ,  NAGLER, Arnon

    IPC: A61K31/517

    CPC classification number: A61K31/517

    Abstract: A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R 1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R 2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R 3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.

    Abstract translation: 与药学上可接受的载体组合的化合物，所述化合物具有下式：其中：R 1是氢，卤素，硝基，苯并，低级烷基，苯基和低级 烷氧基; R 2是由羟基，乙酰氧基和低级烷氧基组成的组的成员; 且R 3是由氢和低级链烯氧基 - 羰基组成的组的成员; n为1或2; 及其药学上可接受的盐; 用于治疗或预防骨骼肌纤维化和/或用于诱导骨骼肌再生。

    ANTI-METASTATIC AND ANTI-ANGIOGENIC PHARMACEUTICAL COMPOSITIONS
    7.
    发明申请
    ANTI-METASTATIC AND ANTI-ANGIOGENIC PHARMACEUTICAL COMPOSITIONS 审中-公开
    抗生物和抗血管生成药物组合物

    公开(公告)号：WO1997000077A1

    公开(公告)日：1997-01-03

    申请号：PCT/IL1996000012

    申请日：1996-06-12

    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD. ,  BAR-SHAVIT, Rachel

    Inventor： HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD.

    IPC: A61K38/00

    CPC classification number: C12N9/6429 ,  A61K38/00 ,  C07K16/40 ,  C12Y304/21005 ,  G01N33/5017 ,  G01N33/574 ,  G01N33/6893

    Abstract: The present invention concerns novel pharmaceutical compositions for the treatment of cancer, either by inhibition of the tumor metastatic tendency or alternatively by inhibiting formation of new blood vessels (angiogenesis) and thus depriving the tumor from its blood source. The active compound in the pharmaceutical compositions of the invention is a fragment of the Thrombin B-chain comprising the sequence Arg-Gly-Asp in an exposed orientation, or modified thrombin in which the naturally cryptic Arg-Gly-Asp sequence has been modified so that it is in an exposed orientation.

    Abstract translation: 本发明涉及通过抑制肿瘤转移倾向或通过抑制新血管形成（血管发生）并因此使肿瘤从其血源中消失来治疗癌症的新型药物组合物。 本发明的药物组合物中的活性化合物是包含暴露方向的序列Arg-Gly-Asp的凝血酶B链的片段或修饰的凝血酶，其中天然的神经精氨酸-Gly-Asp序列已被修饰 它处于暴露的方向。

    IN VITRO CONSTRUCTION OF SV40 VIRUSES AND PSEUDOVIRUSES
    9.
    发明申请
    IN VITRO CONSTRUCTION OF SV40 VIRUSES AND PSEUDOVIRUSES 审中-公开
    SV40病毒和PSEUDOVIRUSES的体外构建

    公开(公告)号：WO1997017456A1

    公开(公告)日：1997-05-15

    申请号：PCT/IL1996000143

    申请日：1996-11-06

    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD. ,  SANDALON, Ziv ,  OPPENHEIM, Amos, B. ,  OPPENHEIM, Ariella

    Inventor： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD.

    IPC: C12N15/86

    CPC classification number: C07K14/005 ,  A61K48/00 ,  C12N15/86 ,  C12N15/87 ,  C12N2710/22022 ,  C12N2710/22043

    Abstract: The invention relates to constructs capable of infecting mammalian cells comprising at least one semi-purified or pure SV40 capsid protein and a constituent selected from the group consisting of an exogenous DNA, a vector comprising an exogenous DNA, an exogenous RNA, a vector comprising an exogenous RNA, an exogenous protein or peptide product, and antisense RNA, ribozyme RNA or any RNA or DNA which inhibits or prevents the expression of undesired protein(s) in said mammalian cell and optionally further comprising operatively linked regulatory elements sufficient for the expression and/or replication of said exogenous protein in a mammalian cell. The protein product is preferably a therapeutic protein or peptide product which is not made or contained in mammalian cells, or is made or contained in such cells in abnormally low amount, or is made or contained in such cells in defective form, or is made or contained in mammalian cells in physiologically abnormal or normal amount and can be an enzyme, a receptor, a structural protein, a regulatory protein or a hormone. The invention further relates to a method for the in vitro construction of SV40 viruses or pseudoviruses constructs according to the invention. In a further aspect, the invention relates to mammalian, preferably human cells infected with the constructs of the invention or with constructs obtained by any of the methods of the invention. Still further, the invention relates to a method of providing a therapeutic DNA, RNA, protein or peptide product or antisense RNA to a patient in need of such product by administering to the patient a therapeutically effective amount of the SV40 viruses or pseudoviruses of the invention or a therapeutically effective amount of infected cells according to the invention. Pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of the SV40 viruses or pseudoviruses according to the invention or a therapeutically effective amount of infected cells according to the invention are also within scope of this application.

    Abstract translation: 本发明涉及能够感染哺乳动物细胞的构建体，其包含至少一种半纯化或纯化的SV40衣壳蛋白和选自外源DNA，包含外源DNA的载体，外源性RNA，包含 外源性RNA，外源蛋白质或肽产物，以及反义RNA，核酶RNA或任何抑制或阻止所述哺乳动物细胞中不希望的蛋白质表达的任何RNA或DNA，以及任选地还包括足以用于表达和/ /或所述外源蛋白在哺乳动物细胞中的复制。 蛋白质产物优选是不是在哺乳动物细胞中制备或包含在哺乳动物细胞中或者以非常低的量制备或包含在这样的细胞中的治疗性蛋白质或肽产物，或者以这些细胞的形式制备或包含在这些细胞中， 包含在生理学异常或正常量的哺乳动物细胞中，并且可以是酶，受体，结构蛋白，调节蛋白或激素。 本发明还涉及用于体外构建根据本发明的SV40病毒或假病毒构建体的方法。 在另一方面，本发明涉及感染本发明构建体的哺乳动物，优选人类细胞，或与通过本发明的任何方法获得的构建体。 此外，本发明涉及通过向患者施用治疗有效量的本发明的SV40病毒或假病毒，向需要这种产品的患者提供治疗性DNA，RNA，蛋白质或肽产物或反义RNA的方法 或治疗有效量的根据本发明的感染细胞。 包含治疗有效量的根据本发明的SV40病毒或假病毒或根据本发明的治疗有效量的感染细胞的药物组合物也在本申请的范围内。

    A METHOD AND KIT FOR EVALUATING THE METASTATIC TENDENCY OF TUMORS
    10.
    发明申请
    A METHOD AND KIT FOR EVALUATING THE METASTATIC TENDENCY OF TUMORS 审中-公开
    一种评估肿瘤转移倾向的方法和试剂盒

    公开(公告)号：WO1997007387A2

    公开(公告)日：1997-02-27

    申请号：PCT/IL1996000077

    申请日：1996-08-08

    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD. ,  BAR-SHAVIT, Rachel

    Inventor： HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD.

    IPC: G01N00/00

    CPC classification number: C07K14/705 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  G01N33/57492 ,  G01N33/86 ,  G01N2333/974

    Abstract: The present invention concerns a method for evaluating the metastatic tendency of tumor cells by determining the level of expression (mRNA level) of the gene coding for the thrombin receptor (ThR) or by determining the level of the thrombin receptor present on the membranes or within the tumor cells. A high level of either of the above indicates a high metastatic tendency, a low level indicates a low metastatic tendency and an intermediate level indicates a moderate metastatic tendency. The present invention further concerns a kit for use in the above method.

    Abstract translation: 本发明涉及通过评估编码凝血酶受体（ThR）的基因的表达水平（mRNA水平）或评估凝血酶受体浓度来评估肿瘤细胞转移趋势的方法。 存在于膜上或肿瘤细胞内。 高度的基因，其编码的凝血酶受体的表达的指示高转移性倾向，低度表达或低浓度的指示低转移倾向和表达或中间浓度的中间电平示出了中间转移倾向 。 本发明还涉及用于实施上述方法的试剂盒。

Patent Agency Ranking